- Open Access
Erratum to: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice
Molecular Neurodegeneration volume 8, Article number: 26 (2013)
Correction to LaClair et al.: Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Molecular Neurodegeneration 2013 8:18.
After publication of this work , we were alerted to an error in the reported cohort size used for the Radial Arm Water Maze as referenced from . The correct cohort size reported in  is n=8-13 for each group of mixed gender animals. In addition, it came to our attention that our analysis of a potential false-positive treatment effect caused by gender differences, and therefore bexarotene’s inability to rescue cognitive decline, may appear to be contradicted by the statement that it “was equally effective in both genders” of transgenic mice . However, direct experimental data supporting this statement is not presented. In addition, this statement does not address any differences in the performance of each gender, only that bexarotene appears effective in each gender separately, and the statistical significance of this reported effect remains unknown. Therefore, we maintain that the currently published cognitive preclinical data, including our own, do not validate the potential of bexarotene for Alzheimer’s therapy.”
LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AS, Troncoso JC, Wong PC: Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener. 2013, 8: 18-10.1186/1750-1326-8-18.
Fitz NF, Cronican AA, Lefterov I, Koldamova R: Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science Tech. Comments. 2013, 340: 924-
The online version of the original article can be found at 10.1186/1750-1326-8-18
Katherine D LaClair, Kebreten F Manaye contributed equally to this work.
About this article
Cite this article
LaClair, K.D., Manaye, K.F., Lee, D.L. et al. Erratum to: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegeneration 8, 26 (2013). https://doi.org/10.1186/1750-1326-8-26